New drug combo aims to tame tough blood cancer
NCT ID NCT03661307
Summary
This study is testing a combination of three drugs—quizartinib, decitabine, and venetoclax—to treat acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It is for older adults who are not candidates for standard intensive chemotherapy or for those whose disease has returned. The main goals are to find the safest dose and see how well the combination works to control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.